DNLI
Price
$28.46
Change
-$1.17 (-3.95%)
Updated
Nov 14, 04:00 PM (EDT)
109 days until earnings call
PGEN
Price
$0.88
Change
-$0.04 (-4.35%)
Updated
Nov 14, 04:00 PM (EDT)
104 days until earnings call
Ad is loading...

DNLI vs PGEN

Header iconDNLI vs PGEN Comparison
Open Charts DNLI vs PGENBanner chart's image
Denali Therapeutics
Price$28.46
Change-$1.17 (-3.95%)
Volume$118.28K
CapitalizationN/A
Precigen
Price$0.88
Change-$0.04 (-4.35%)
Volume$69.19K
CapitalizationN/A
DNLI vs PGEN Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
DNLI vs. PGEN commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and PGEN is a Hold.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (DNLI: $29.64 vs. PGEN: $0.92)
Brand notoriety: DNLI and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 184% vs. PGEN: 88%
Market capitalization -- DNLI: $4.3B vs. PGEN: $267.97M
DNLI [@Biotechnology] is valued at $4.3B. PGEN’s [@Biotechnology] market capitalization is $267.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 6 TA indicator(s) are bullish while PGEN’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 6 bullish, 4 bearish.
  • PGEN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than PGEN.

Price Growth

DNLI (@Biotechnology) experienced а +0.30% price change this week, while PGEN (@Biotechnology) price change was +2.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.83%. For the same industry, the average monthly price growth was +3.51%, and the average quarterly price growth was +6.16%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 03, 2025.

PGEN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-1.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($4.3B) has a higher market cap than PGEN($268M). DNLI YTD gains are higher at: 38.117 vs. PGEN (-31.664). PGEN has higher annual earnings (EBITDA): -130.97M vs. DNLI (-486.71M). DNLI has more cash in the bank: 896M vs. PGEN (19.5M). PGEN has less debt than DNLI: PGEN (6.34M) vs DNLI (48.8M). PGEN has higher revenues than DNLI: PGEN (4.39M) vs DNLI (1.27M).
DNLIPGENDNLI / PGEN
Capitalization4.3B268M1,606%
EBITDA-486.71M-130.97M372%
Gain YTD38.117-31.664-120%
P/E RatioN/AN/A-
Revenue1.27M4.39M29%
Total Cash896M19.5M4,595%
Total Debt48.8M6.34M770%
FUNDAMENTALS RATINGS
DNLI vs PGEN: Fundamental Ratings
DNLI
PGEN
OUTLOOK RATING
1..100
1213
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
9297
PRICE GROWTH RATING
1..100
3861
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (61) in the null industry is in the same range as DNLI (93) in the Biotechnology industry. This means that PGEN’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Profit vs Risk Rating (79) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that DNLI’s stock grew similarly to PGEN’s over the last 12 months.

DNLI's SMR Rating (92) in the Biotechnology industry is in the same range as PGEN (97) in the null industry. This means that DNLI’s stock grew similarly to PGEN’s over the last 12 months.

DNLI's Price Growth Rating (38) in the Biotechnology industry is in the same range as PGEN (61) in the null industry. This means that DNLI’s stock grew similarly to PGEN’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that DNLI’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIPGEN
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VINAX141.350.16
+0.11%
Vanguard Industrials Index Admiral
FIZRX40.03-0.11
-0.27%
Delaware Opportunity R
RYKIX111.19-0.50
-0.45%
Rydex Banking Inv
ESPTX10.22-0.07
-0.68%
UBS International Sustainable Equity P2
ETCHX32.12-0.24
-0.74%
Eventide Healthcare & Life Sciences C